Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Assets (2016 - 2025)

Historic Current Assets for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $344.8 million.

  • Myriad Genetics' Current Assets rose 1759.89% to $344.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $344.8 million, marking a year-over-year increase of 1759.89%. This contributed to the annual value of $298.0 million for FY2024, which is 497.45% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Current Assets is $344.8 million, which was up 1759.89% from $284.3 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Current Assets ranged from a high of $538.9 million in Q2 2021 and a low of $261.6 million during Q1 2023
  • Moreover, its 5-year median value for Current Assets was $298.0 million (2024), whereas its average is $342.0 million.
  • Per our database at Business Quant, Myriad Genetics' Current Assets skyrocketed by 6246.61% in 2021 and then plummeted by 4335.81% in 2022.
  • Quarter analysis of 5 years shows Myriad Genetics' Current Assets stood at $484.8 million in 2021, then plummeted by 43.36% to $274.6 million in 2022, then grew by 14.2% to $313.6 million in 2023, then dropped by 4.97% to $298.0 million in 2024, then increased by 15.7% to $344.8 million in 2025.
  • Its Current Assets was $344.8 million in Q3 2025, compared to $284.3 million in Q2 2025 and $287.2 million in Q1 2025.